NCT04575701

Long-term Outcome of TNF Alpha Therapy in IBD

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 538 (actual)
• Sponsor: Medical University of Graz · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease (IBD) under TNF-alpha antibody therapy over a period of 20 years

Detailed description

Long-term results published so far show that over the years a large part of patients have to stop TNF Alpha antibody therapy in IBD. Reasons are mostly loss of effectiveness or intolerance or side effects. Reasons for the termination are usually poorly characterized with regard to the exact reason and time. As a consequence, the aim of this retrospective study is to assess the outcome of patients with inflammatory bowel disease under TNF-alpha antibody therapy over a period of 20 years

Conditions

• IBD

Interventions

Type	Name	Description
OTHER	TNF Alpha therapy	Retrospective analysis of outcome of first TNF Alpha therapy

Timeline

• Start date: 2019-05-01
• Primary completion: 2020-06-01
• Completion: 2020-07-01
• First posted: 2020-10-05
• Last updated: 2021-02-25

Locations

1 site across 1 country: Austria